News 2023-07-28
[Important Notice] Porton Announcement Regarding the Change of Email Domain
Dear valued customers and partners,
We would like to extend our gratitude for your continuous support towards Porton Pharma Solutions Ltd. In order to further enhance the company's brand recognition, adapt to our global development strategy, improve communication efficiency, and protect each other's information security, we have decided to change our email domain name from porton.cn to portonpharma.com.
We will be discontinuing the use of the old email addresses and will automatically forward all emails sent to the old addresses to the new address in the coming weeks or so. To avoid any unnecessary delays, we strongly recommend that you start using the new email address to contact us starting from August 13, 2023.
We look forward to maintaining closer contact with you and achieving greater business success together. If you have any questions or need further assistance, please feel free to contact us at any time.
We apologize for any inconvenience caused by this change and appreciate your understanding!
Website: www. portonpharma.com
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
